Back to search
FDAFDA · Food and drugs·Recall number D-0684-2018

Lupin Cefdinir powder for Oral Suspension USP, 250 mg/5 mL in (a) 60 mL packs ( NDC 68180-723-20) and (b) 100 mL packs ( 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202

Published April 25, 2018 · Recall initiated: March 27, 2018

Summary

FDA records drug Class II recall D-0684-2018, published April 25, 2018 and initiated March 27, 2018. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 40,824 bottles; Lot: Lot # F602241; Exp. 10/18 Lot # F602577; Exp. 11/18 Lot # F700036; Exp. 12/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email if CEFDINIR has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CEFDINIR
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide
UPC
0368180723042
Lot
Lot # F602241; Exp. 10/18 Lot # F602577; Exp. 11/18 Lot # F700036; Exp. 12/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lupin Cefdinir powder for Oral Suspension USP, 250 mg/5 mL in (a) 60 mL packs ( NDC 68180-723-20) and (b) 100 mL packs ( 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 recalled?

Yes. FDA published recall D-0684-2018 on April 25, 2018. Reported hazard: Superpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CEFDINIR. UPC: 0368180723042.